Health · September 4, 2026 · 8 min read

Tesamorelin for Body Recomposition: Why Visceral Fat Matters More Than the Number on the Scale

Learn how tesamorelin works, why visceral fat matters for body composition, and how clinician-guided peptide therapy may fit alongside GLP-1 weight-loss treatment.

Losing weight and changing your body composition aren't necessarily the same thing.

You can watch the number on the scale fall while still wondering: Am I losing the kind of weight I actually want to lose?

For people focused on looking leaner, improving body composition, and getting more from the work they're putting into nutrition and training, that distinction matters.

One compound generating significant interest in this area is tesamorelin.

What is tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, or GHRH. Rather than supplying growth hormone directly, it stimulates the pituitary gland to increase the body's own growth hormone secretion.

Rise's clinical product guide categorizes tesamorelin alongside sermorelin and CJC-1295 + ipamorelin as growth-hormone secretagogues. Of the three, tesamorelin is particularly associated with visceral-fat reduction.

That last distinction is important. Tesamorelin isn't simply another "weight-loss peptide."

Tesamorelin and visceral fat

Visceral adipose tissue is the fat stored deeper inside the abdomen around internal organs. It is different from the subcutaneous fat you can pinch beneath your skin.

Tesamorelin has unusually strong clinical evidence for affecting this type of fat—but in a specific patient population. Tesamorelin is FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. In FDA-reviewed clinical trials, visceral adipose tissue decreased approximately 14–18% at 26 weeks in tesamorelin groups, depending on the study.

A randomized clinical trial also found significant reductions in visceral and liver fat among people with HIV-associated abdominal fat accumulation.

Those findings are compelling, but there's an important distinction: using tesamorelin for general body recomposition or visceral-fat reduction in people without HIV-associated lipodystrophy is an off-label use. The evidence from HIV-associated lipodystrophy cannot simply be assumed to produce identical results in otherwise healthy adults.

Why are people interested in tesamorelin for body recomposition?

Because body recomposition isn't just about weighing less. Someone trying to get into great shape may care about:

• reducing abdominal and visceral fat;
• maintaining or improving lean body composition;
• getting more definition as overall body fat falls;
• supporting training, nutrition, recovery and metabolic health.

Rise's patient guide identifies visceral-fat reduction as the primary reason tesamorelin may be prescribed within this category. That makes tesamorelin conceptually different from a traditional appetite-focused weight-loss medication.

Tesamorelin + GLP-1 therapy: a body-composition conversation

GLP-1 medications such as semaglutide and tirzepatide have transformed medical weight management. But once weight starts coming off, another question becomes increasingly important: What is the weight you're losing made of?

Research shows that GLP-1-based therapies predominantly reduce fat, but some lean mass can also be lost during substantial weight reduction. A recent meta-analysis found lean mass represented roughly 25–39% of total weight lost, depending on the incretin therapy studied. Resistance training was associated with a substantially more favorable lean-mass profile.

That does not mean tesamorelin has been proven to prevent GLP-1-associated muscle loss. It hasn't. It does mean that sophisticated medical weight management should increasingly look beyond the scale toward body composition.

For someone using a GLP-1, the foundation remains adequate protein, resistance training, appropriate calories and clinical monitoring. A qualified clinician can then determine whether an additional therapy aimed at a different physiological pathway makes sense.

What should you expect?

According to the Rise clinical guide, tesamorelin is typically administered as a subcutaneous injection. The guide describes nightly dosing and treatment cycles for the wellness protocol it covers, with periodic clinician reassessment.

Tesamorelin isn't appropriate for everyone. The guide identifies important exclusions including pregnancy, certain cancers or tumors, elevated IGF-1, certain cardiac conditions and other growth-hormone therapies. FDA labeling likewise includes significant precautions, including active malignancy and pregnancy.

Stop chasing weight loss. Start thinking about body composition.

The goal shouldn't necessarily be to become the lightest version of yourself. It may be to become the strongest, leanest and healthiest version of yourself at a sustainable weight.

At Rise Wellness & Longevity, our approach is individualized. We look at your goals, health history, current medications, training and weight-loss strategy and connect you with clinician-guided treatment options when medically appropriate.

Ready to find out whether tesamorelin belongs in your body-recomposition strategy? Start your Rise evaluation today.

Medical disclaimer: This article is educational and does not constitute medical advice. Tesamorelin's FDA-approved indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Other uses discussed are off-label and require evaluation and prescribing by a qualified clinician.

Sources

Find your protocol All articles